New COVID-19 Variant EG.5 Now Dominant in U.S., CDC Says
Medically reviewed by Drugs.com.
By Physician’s Briefing Staff HealthDay Reporter
TUESDAY, Aug. 8, 2023 -- A variant nicknamed Eris now accounts for the largest proportion of new COVID-19 infections across America.
About 17.3 percent of U.S. COVID-19 cases are believed to have been caused by the variant, formally known as EG.5, in early August, according to the U.S. Centers for Disease Control and Prevention. That number is 7.5 percent higher than it was in early July.
Other dominant variants include XBB.1.16, with 15.6 percent of cases, and XBB.2.23, with 11.2 percent of cases, CDC data show. Another 10.3 percent of COVID-19 cases are from XBB.1.5, while 8.6 percent of cases were caused by an XBB-related variant known as FL.1.5.1.
Experts say EG.5 might be beating out other variants because it appears to have a "slightly beneficial mutation," CBS News reported. Eris is one of several closely related omicron subvariants that have been competing for dominance in recent months. All of these variants are descendants of the XBB strain, which is the target of this fall's COVID-19 vaccines.
"While the emergency of COVID has been lifted and we're no longer in a crisis phase, the threat of COVID is not gone. So, keeping up with surveillance and sequencing remains absolutely critical," Maria Van Kerkhove, M.D., the World Health Organization technical lead for COVID-19, said in a statement last month.
Because the CDC has slowed its tracking of COVID-19 variants, it was not able to project the emergence of EG.5 until now since only California, Georgia, and New York have had enough sequences to update national data, CDC officials said. While tens of thousands of sequences were uploaded to virus databases earlier in the pandemic, now that is less than 2,000, CBS News reported.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Further Support and Information on COVID-19
Read this next
No Decline in Cardiovascular Events Seen With COVID-19 Vaccine After Acute Coronary Syndromes
MONDAY, June 3, 2024 -- Patients who have received at least one COVID-19 vaccine dose after acute coronary syndromes do not have a reduced risk for cardiovascular events...
Mortality Higher for COVID-19 Hospitalization Than for Flu in 2023/2024 Season
WEDNESDAY, May 22, 2024 -- In fall/winter 2023/2024, the risk for death in patients hospitalized for COVID-19 was greater than the risk for death in patients hospitalized for...
Global Life Expectancy, Disease Burden Set to Keep Improving
WEDNESDAY, May 22, 2024 -- Life expectancy and age-standardized disease burden are expected to continue improving between 2022 and 2050, according to the Global Burden of Disease...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.